Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients

Frank Breitenbuecher1*, Sandra Hoffarth1, Karl Worm2, Diana Cortes-Incio1, Thomas C. Gauler1,3, Jens Köhler1, Thomas Herold2,5,6, Kurt Werner Schmid2, Lutz Freitag4, Stefan Kasper1, Martin Schuler1,3,6

1 Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, 2 Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, 3 Division of Thoracic Oncology, Ruhrlandklinik, West German Lung Center, University Duisburg-Essen, Essen, Germany, 4 Division of Interventional Pneumology, Ruhrlandklinik, West German Lung Center, University Duisburg-Essen, Essen, Germany, 5 German Cancer Research Center, Heidelberg, Germany, 6 German Cancer Consortium (DKTK), Heidelberg, Germany

Abstract

Background: Oncogenic mutations are powerful predictive biomarkers for molecularly targeted cancer therapies. For mutation detection patients have to undergo invasive tumor biopsies. Alternatively, archival samples are used which may no longer reflect the actual tumor status. Circulating tumor cells (CTC) could serve as an alternative platform to detect somatic mutations in cancer patients. We sought to develop a sensitive and specific assay to detect mutations in the EGFR gene in CTC from lung cancer patients.

Methods: We developed a novel assay based on real-time polymerase chain reaction (PCR) and melting curve analysis to detect activating EGFR mutations in blood cell fractions enriched in CTC. Non-small-cell lung cancer (NSCLC) was chosen as disease model with reportedly very low CTC counts. The assay was prospectively validated in samples from patients with EGFR-mutant and EGFR-wild type NSCLC treated within a randomized clinical trial. Sequential analyses were conducted to monitor CTC signals during therapy and correlate mutation detection in CTC with treatment outcome.

Results: Assay sensitivity was optimized to enable detection of a single EGFR-mutant CTC/mL peripheral blood. CTC were detected in pretreatment blood samples from all 8 EGFR-mutant lung cancer patients studied. Loss of EGFR-mutant CTC signals correlated with treatment response, and its reoccurrence preceded relapse.

Conclusions: Despite low abundance of CTC in NSCLC oncogenic mutations can be reproducibly detected by applying an unbiased CTC enrichment strategy and highly sensitive PCR and melting curve analysis. This strategy may enable non-invasive, specific biomarker diagnostics and monitoring in patients undergoing targeted cancer therapies.

Citation: Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler TC, et al. (2014) Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients. PLoS ONE 9(1): e85350. doi:10.1371/journal.pone.0085350

Editor: Javier S. Castresana, University of Navarra, Spain

Received October 1, 2013; Accepted December 4, 2013; Published January 21, 2014

Copyright: © 2014 Breitenbuecher et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by an Oncology Center of Excellence grant from the German Cancer Aid (Deutsche Krebshilfe, www.krebshilfe.de) to the West German Cancer Center, intramural research funds of the Medical Faculty of the University Duisburg-Essen (IFORES to M.S.), and an institutional research grant from Boehringer Ingelheim (www.boehringer-ingelheim.com/to F.B. and M.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have read the journal’s policy and have the following conflicts. FB: Institutional research funding (Boehringer Ingelheim). TG: Travel support, honoraria and consulting fees (Boehringer Ingelheim, Pfizer, Roche, Lilly). JK: Honoraria, travel support (Boehringer Ingelheim, Amgen, Roche). SK: Consulting fees, honoraria, travel support (Merck-Serono, Amgen, Roche). MS: Institutional research funding, consulting fees (Boehringer Ingelheim). All remaining authors have declared no conflicts of interest. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: Frank.Breitenbuecher@uk-essen.de

Introduction

Activating EGFR mutations define a group of genetically dependent pulmonary adenocarcinomas, which are almost exclusively sensitive to EGFR tyrosine kinase inhibitors (EGFR-TKI). Therapeutic decisions in patients with metastatic NSCLC are guided by the EGFR mutation status, which is determined in tumor biopsies [1]. Acquisition of such biopsies may be hazardous to the patient. Moreover, a single tumor biopsy may not fully reflect the status of a metastatic cancer. Non-invasive methods for repetitive determination of prognostic and predictive genetic biomarkers could facilitate personalized cancer therapy.

Circulating tumor cells (CTC) have been described in several cancer entities. Enumeration of CTC has been correlated with clinical outcomes and treatment response [2–6]. These studies have applied immunocytochemical detection of protein markers, mostly neglecting genomic biomarkers such as EGFR mutation status. In contrast to leukemias, where malignant cells are abundantly present in the peripheral blood, CTC are rare in
patients with solid tumors and a large variability of CTC counts has been observed [5,3,7-9]. CTC detection based on epithelial markers such as EpCAM or cytokeratins (CK) may overlook tumor cells undergoing epithelial-mesenchymal transition (EMT) [10].

Here we describe a novel highly sensitive and specific strategy to detect CTC harboring somatic mutations in NSCLC patients. As a proof-of-concept model we have used in-frame deletions in the EGFR exon 19 (DelEx19), which comprise approximately 48% of all EGFR mutations [11]. We were able to detect EGFR DelEx19-mutated CTC prior to therapy in all patients with EGFR mutational status known from tumor biopsies that were assessed. Moreover, clearance of mutation-positive CTC correlated with treatment response and disease control.

Materials and Methods

Genomic DNA preparation

Genomic DNA was isolated from PBMCN and cell lines using the NucleoSpin® Blood Kit (Macherey-Nagel, Düren, Germany). If necessary, genomic DNA was amplified using the REPLI-g Midi Kit (QIAGEN, Hilden, Germany). Genomic DNA from cell lines or plasmid DNA (pcDNA3.1V5/HisTOPO, Clontech, Mountain View, USA) encoding a human EGFR cDNA sequence harboring a 15 bp deletion (delE746-A750) were serially diluted. Cell lines A431 (EGFR wild type, wt) and NCI-HCC-827 (EGFR delE746-A750) were obtained from DSMZ (Braunschweig, Germany) and EGFR mutation status was verified by Sanger sequencing.

PCR amplification and EGFRDelEx19 mutation detection

*EGFR* DelEx19 mutations were detected by melting curve analysis on a LightCycler 480 (Roche, Mannheim, Germany). Optimal mutation detection sensitivity was achieved by a combination of specifically designed hybridization probes imperfectly binding to *EGFR* Exon 19 sequences harboring a deletion at amino acid position 746 or 747, locked-nucleic acids (LNA) suppressing amplification of wildtype *EGFR* sequences and preventing hybridization of probes to wildtype *EGFR* Exon 19 sequences and finally applying asymmetric PCR conditions preferentially amplifying the DNA strand hybridization probes bind to. All parameters were empirically optimized to achieve optimal assay sensitivity. Each reaction (20 µl) contained 50 ng genomic DNA, 2 pmol forward and 2 pmol reverse primer (Eurofins MWG, Ebersberg, Germany; Ex198: 5’-GTCATTCTTGTCTCTTGATAGGG-3’, Ex199R: 5’-GGGCCTGAGGTGAGACG-3’), 2 µl LightCyclerFastStart DNA Master HybProbe (Roche, Mannheim, Germany), 3 pmol hybridization probe 1 (“anchor”: 5’-LC640-ATTTTAACCTTCTACCTGAGATCCAG-PH) and 3 pmol hybridization probe 2 (“sensor”: 5’-TAATTCCTTGATAGGACGGGFL) (TIB Molbiol, Berlin, Germany). All PCR reactions were carried out with and without addition of 6 pmol locked-nucleic acid (LNA: 5’TAAATTTCTTGATAGNH2; TIB Molbiol, Berlin, Germany).

Immunomagnetic enrichment of circulating tumor cells from peripheral blood

Peripheral blood (20 mL) was collected in sodium citrate tubes (Sarstedt, Nümbrecht, Germany). PBMCN were isolated by density gradient centrifugation. The median enrichment of WBG by density gradient centrifugation was approximately threefold. EpCam-positive cells and CD45-negative cells were enriched in two parallel reactions using anti-EpCAM (CD326) and anti-CD45 microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). Genomic DNA was isolated from the resulting four sample fractions (CD45−, CD45+, CD326− and CD326+) and subjected to real time-PCR and melting curve analysis.

Mutation detection by sequence analysis

For sequence analysis, genomic DNA of selected samples was amplified by whole genome amplification (WGA) using the REPLI-g Midi Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. All sequence reads were generated by a commercial sequencing service (LGC Genomics, Berlin, Germany) on a Roche 454 GS FLX® Titanium (Roche, Branford, USA) and analyzed using CLC genomics workbench (CLCbio, Aarhus, Denmark). Reads were imported into CLC genomics workbench (using *.*.fasta and *.*.qual data), trimmed and mapped to a reference including *EGFR* exon 19 sequence as well as 50 bp up- and downstream intron sequences. The median coverage for exon 19 sequences was 7,316 reads (range 3,717–17,368).

Patient samples/Ethics statement

Peripheral blood samples were obtained from patients with *EGFR* mutant and *EGFR* wt NSCLC following written informed consent. The study was approved by the Ethics Committee of the Medical Faculty of the University Duisburg-Essen (AZ. 10-4359).

Statistics

Exploratory statistical analyses were conducted using GraphPad Prism 4 (GraphPad Software, La Jolla, USA) and IBM SPSS Statistics version 19 (IBM, Armonk, USA).

Results

Sensitivity and specificity of mutation detection

In order to determine the threshold for *EGFR* DelEx19 mutation detection by melting curve analysis, we initially studied serial dilutions of genomic DNA from *EGFR* wt A431 cells and NCI-HCC-827 cells harboring an *EGFR* DelEx19 mutation (Figure 1a). By optimization of PCR parameters and inclusion of wt *EGFR*-specific LNA the sensitivity of detection was enhanced to 0.1% *EGFR*DelEx19-mutant sequences (Figure 1b). In further serial dilutions of plasmid DNA (pcDNA3.1.EGFRdelE746-A750) the mutation detection threshold was as low as 0.01% (data not shown).

Next, we spiked blood samples from healthy volunteers with defined cell numbers of NCI-HCC-827 cells. Samples were processed as described to enrich spiked tumor cells and all resulting cell fractions were subjected to genomic DNA isolation, real time PCR and melting curve analysis. In these experiments the reproducible lower limit of detection was 1 *EGFR*-mutant cell per 1 mL peripheral blood (Figure 1c, d). This protocol was then applied to blood samples from three NSCLC patients with *EGFR* wildtype tumors and two healthy volunteers. DNA isolated from all cell fractions tested negative for *EGFR* DelEx19 mutations (Suppl. Figure S1 a–c).

Assay validation in clinical samples

To validate our strategy for CTC-enrichment and mutation detection we prospectively obtained peripheral blood samples from 8 patients with metastatic NSCLC harboring *EGFR* DelEx19 mutations, treated at our center within the LUX-Lung 3 study (EudraCT-No. 2008-005615-18; [12]). Per study inclusion criteria all patients had histologically confirmed, medically untreated stage IIIIB/IV pulmonary adenocarcinoma (Table 1). All *EGFR* mutations were confirmed by central analysis.
A blood sample was designated “negative” for EGFR-mutant CTC if no mutation signal was obtained by real-time PCR analysis of genomic DNA isolated from all cell fractions (CD45^+ , CD45^− , CD326^+ and CD326^− ) obtained at the respective time point. Based on our titration experiments this indicated that EGFR-mutant CTC dropped below 1 cell/mL blood. In case an EGFR DelEx19 mutation was detected in genomic DNA from at least one cell fraction the sample was declared “positive” for EGFR-mutant CTC.

Base line samples were obtained within 7 days prior to study therapy, sequential blood samples were taken at regular intervals under treatment and follow-up. Upon clinical progression and/or end of therapy an additional blood sample was obtained. In total 148 blood samples were collected over a period of 36 months and analyzed for the presence of EGFR-mutant CTC (median: 12 samples/patient; range 7–56). Base line blood samples from 8 of 8 patients (100%) were “positive” for EGFR-mutant CTC. Interestingly, sequential samples from 4 of 8 patients turned “negative” for EGFR-mutant CTC within a median of 34 days (range: 20–84 days) of study treatment (Figure 2 a–j). “CTC negativity” (i.e. less than 1 EGFR DelEx19-mutated cell per milliliter blood) persisted for a median of 109 days (range: 35–199 days). Genomic DNA from samples displaying a strong EGFR DelEx19 mutation signal in our newly developed assay (shown in Figures 2A–2C and 2F), was analyzed on a Roche 454 GS FLX+ Titanium sequencer. To our surprise, in none of these samples a deletion in EGFR Exon 19 could be detected (data not shown).

**Association of EGFR mutant CTC with clinical outcomes**

Based on this observation we queried the association of EGFR-mutant CTC with treatment response and duration in our validation cohort. We defined a patient as “EGFR-mutant CTC
Table 1. Patient data and demographics.

| Patient ID | Sex | Age (years) | Best treatment response | EGFR mutation | CTC detection baseline | Days on study medication (TTF) | CTC clearance | Best treatment | EGFR mut. tumor biopsy | EGFR mut. CTC | Study medication |
|------------|-----|-------------|-------------------------|---------------|-----------------------|-------------------------------|--------------|-----------------|----------------------|--------------|------------------|
| 018        | m   | 50          | SD                      |               |                       | 84                           |              |                 |                      |              | P/C              |
| 015        | f   | 61          | PR                      | DelEx19       | Y                     | 252                           |              |                 |                      |              | A                |
| 042        | f   | 66          | SD                      | DelEx19       | N                     | 148                           |              |                 |                      |              | A                |
| 041        | m   | 65          | PR                      | DelEx19, T790M| Y                     | 189                           |              |                 |                      |              | A                |
| 017        | m   | 63          | PR                      | DelEx19, T790M| Y                     | 145                           |              |                 |                      |              | A                |
| 016        | f   | 42          | PD                      | DelEx19       | N                     | 108                           |              |                 |                      |              | A                |
| 030        | f   | 64          | PR                      | DelEx19       | Y                     | 173                           |              |                 |                      |              | A                |

Demographics, treatment and outcome of the validation cohort comprising patients with stage IV pulmonary adenocarcinoma. All mutation analyses on tumor samples were conducted by a central laboratory within the LUX-Lung 3 study. Abbreviations: m, male; f, female; TTF, time to treatment failure; SD, stable disease; PR, partial response; PD, progressive disease; P/C, Pemetrexed/Cisplatin; A, Afatinib.

*EGFR mutations detected by central laboratory analysis and additional local mutation testing.

doi:10.1371/journal.pone.0085350.t001

Discussion

Currently, the detection of genetic aberrations in tumor tissues is the clinically most powerful biomarker for stratification of “targeted” pharmacotherapies in metastatic lung cancer [13,14]. Treatment with gefitinib and crizotinib, as well as first-line erlotinib, is conditional on the demonstration of EGFR mutations and ALK rearrangements. Mutation detection is frequently performed in small and/or archival tumor specimens, which may not reflect the current genomic profile at treatment initiation [15]. Moreover, the mutational spectrum of a cancer changes under the selective pressure of a given therapy, which can only be revealed by sequential biopsies. Against this background, the detection of cancer-specific mutations in other formats than tumor biopsies has gained interest. In NSCLC, successful detection of mutated DNA sequences was reported in serum, plasma or bronchoalveolar lavage fluid [16–19]. Nevertheless, most of these reports displayed a level of sensitivity below clinical requirements.

The early systemic dissemination of cancer cells is considered of biological relevance. Using primary antibodies against epithelial markers, disseminated tumor cells and CTC have been detected in bone marrow and blood from patients with various malignancies. Among a large variety of alternative strategies applied for CTC-enrichment and analysis, an automated system for immunocyto-metric detection and quantitation of CTC has been developed, which was validated in breast, prostate, colorectal and lung cancer patients [2,5,8,20–23]. Interestingly, the absolute amount of CTC detected in advanced stage cancer patients varied considerably, depending on CTC-isolation techniques. While high numbers of CTC were detected in patients with small-cell lung cancer, absolute CTC numbers and dynamic range in NSCLC seemed too low for broad clinical applicability. Nevertheless, it has become increasingly clear that CTC populations are phenotypically heterogeneous and epithelial-marker independent enrichment approaches are warranted to display the full picture of CTC in a cancer patient at a given time point. Several recent reports supported this notion by consistently showing higher CTC cleared” if two consecutive blood samples were tested “negative”, i.e. EGFR-mutant CTC counts dropped below 1 cell/mL. “CTC recurrence” was declared when two consecutive blood samples tested “positive” for EGFR-mutant CTC. Results from CTC mutation analysis were correlated with radiological response assessed within the LUX-Lung 3 study. All 4 patients who “cleared” EGFR-mutant CTC achieved disease control, with 3 partial responses (PR) and one stable disease (SD) per RECIST. In 4 patients with persisting CTC in their peripheral blood and who thus failed to “clear” EGFR-mutant CTC only one objective response (PR) was observed, while 2 patients achieved SD and one patient progressive disease (PD). At follow-up all 4 patients with “clearance” of EGFR-mutant CTC developed PD. EGFR-mutant CTC returned to “positive” at a median of 140 days (range 0–960 days) prior to radiologically documented PD. Hence, an increase in EGFR-mutant CTC counts above the threshold of 1 cell/mL could be an early indicator of disease relapse and resistance in patients that have “cleared” CTC. By exploratory statistical analyses we observed a significant association (Spearman-Rho correlation coefficient 0.868, p=0.01) between the duration of “CTC negativity” and the time to treatment failure. Patients who had “cleared” EGFR-mutant CTC below the level of detection showed a significantly prolonged time to treatment failure (median: 355 days; range: 189–1,086 days; p = 0.006, Log-rank test) as compared to patients who remained “positive” for EGFR-mutant CTC (median: 116 days, range: 84–173 days; Fig. 3).
numbers when comparing epithelial-marker-independent CTC enrichment techniques (e.g. enrichment by cell size) with the widely applied CTC isolation by selection of EpCAM and CK-positive cells using the CellSearch system [5,8,24,25].

Against this background we reasoned whether probing for cancer-specific somatic mutations instead of microscopy-based parameters enhances the sensitivity of CTC detection in NSCLC. We have chosen EGFR DelEx19 mutations as a model to develop a highly sensitive, specific and robust method for mutation detection in mixtures of genomic DNA that were extracted from CTC-enriched peripheral blood cell populations. The novel method applied in this study has been designed to detect the vast majority of EGFR DelEx19 mutations, notably all possible mutant variants disrupting codons 746 and 747 of the EGFR gene. In contrast to a prior study analyzing only EpCAM-positive blood cells [26] we have chosen an unbiased, epithelial marker-independent CTC enrichment strategy where samples were split and CTC enrichment was achieved by a dual approach, depleting leucocytes in one half of a sample and selection of EpCAM-positive cells in the other half. This takes into account the phenotypic variability of CTC, which may lose one or several epithelial markers while being shed from a primary tumor or metastases [27–29]. In pilot experiments, Immunofluorescence staining of selected CTC samples from NSCLC patients indeed showed heterogeneous populations of CTCs displaying epithelial, mesenchymal and mixed phenotypes (data not shown). Applying

Figure 2. Detection of EGFR-mutant CTC and treatment outcome in patients with NSCLC harboring EGFR DelEx19 mutation.

Representative examples of EGFR-mutant CTC analyses and clinical course of patients of the prospective validation cohort. All patients were treated within the LUX-Lung 3 study for stage IV EGFR-mutant NSCLC. Treatment course, imaging time points (CT) and time points of CTC analyses are illustrated in E and J. Solid arrows indicate “CTC positivity”, dashed arrows “CTC negativity”. Asterisks indicate time points of the CTC analyses/CT scans shown in A–D, and F–I. (A) Baseline analysis of patient 018 showed strong EGFR DelEx19 signals in two cell fractions (CD326+ and CD45-). (B, C) Sequential analyses in patient 018 reveal strong EGFR DelEx19 signals at least in one relevant cell fraction. (D) Representative CT images from patient 018 at baseline, and at day 84 of study treatment confirming progressive disease. (F) Baseline analysis of patient 017 showing strong EGFR DelEx19 signals in two cell fractions (CD326+ and CD45+). (G, H) Sequential analysis in patient 017 showing decreased (G) and negative (H) EGFR DelEx19 signals in both relevant cell fractions. (I) Representative CT images from patient 017 at baseline, and at day 84 of study treatment confirming a partial response.

doi:10.1371/journal.pone.0085350.g002
this unbiased CTC-enrichment approach, we achieved a 100% detection rate in a pilot cohort of 8 patients with EGFR-mutant NSCLC. Most interestingly, we observed an association of EGFR-mutant CTC with treatment response and outcome. These findings are most likely to be attributed to the novel and highly sensitive mutation detection method applied in this study. It has been recognized for some time that detection of mutations at levels below 1% is not reliably possible by next generation sequencing applications due to intrinsic error rates of this technology [30]. Only very recently improved technologies were reported, rendering detection of mutations at levels of 0.1% and below possible [31,32]. In keeping with these results, we were not able to detect EGFR Del19 mutations by next generation sequencing in genomic DNA of samples displaying unambiguous mutation signals in our newly developed mutation detection assay. These findings indicate that our newly developed mutation detection assay apparently displays higher sensitivity than standard next generation sequencing techniques. Another remarkable aspect of our mutation detection assay was the observation that different EGFR DelEx19 mutations gave rise to different melting curves (see Figure 2 and suppl. Figure S1). This is most likely due to the characteristics of one of the hybridization probes, which is designed to bind to EGFR Exon 19 wildtype sequences in the region of potential deletions leading to the dissociation of the probe during melting curve analysis at different temperatures depending on the sequence of the respective deletion.

While these results are promising, we are aware that the patient population analyzed here is very small and validation in larger patient populations including additional mutations is required. Currently, equally sensitive mutation detection assays covering multiple therapy-relevant regions of the EGFR gene (e.g. codons 1358 and T790) and other oncoproteins are being developed.

In summary, we have described a novel strategy based on CTC enrichment and highly sensitive detection of somatic mutations, which can be applied for mutational profiling and monitoring of treatment efficacy in patients with EGFR-mutant NSCLC. By assay optimization we have shown that the problem of notoriously low CTC counts in stage IV NSCLC can be overcome. This may be another step toward the vision of a “liquid biopsy” for hazard-free molecular diagnostics and disease monitoring in patients with metastatic lung cancer.

Supporting Information

Figure S1 | EGFR DelEx19 mutation analysis in blood samples from NSCLC patients with EGFR–wild type tumors and healthy control persons. Peripheral blood samples from three patients with EGFR–wild type NSCLC (A, B, C) and two healthy volunteers (D, E) were enriched, separated in cellular fractions and subjected to DNA isolation as described. Mutation detected was conducted by real-time PCR and melting curve analysis in the presence of LNA. No EGFR DelEx19 signal was detected. H2O (bottom line) and 50 ng of undiluted genomic DNA of NCI-HCC-827 cells (“control 1”), plasmid DNA containing an EGFR DelEx19 sequence (“control 2”) and A431 cells (“EGFR wildtype control”) were included as negative and positive controls. For clarity only single values of duplicates are shown.

(TIF)

Acknowledgments

We thank all patients for participation in this study. All contributing staff members of the Departments of Medical Oncology, Pathology and Neuropathology, West German Cancer Center, University Hospital Essen, and the Division of Thoracic Oncology and Interventional Pneumology, Ruhrlandklinik, are thanked. Sabrina Schilling and Sarah-Luise Stergarp are acknowledged for excellent technical assistance and Sabine Kasimir-Bauer for helpful discussions and advice. We are grateful to Ivonne Nel and Andreas-Claudius Hoffmann for advice and excellent technical assistance with immunofluorescence stainings. The German Research Foundation (DFG) granted support for publication fees.

Author Contributions

Conceived and designed the experiments: FB SH KW DC-I TG JK TH KWS LF SK MS. Performed the experiments: FB SH KW DC-I TG TH KWS LF SK MS. Analyzed the data: FB SH KW DC-I TG JK TH KWS LF SK MS. Contributed reagents/materials/analysis tools: FB SK MS. Wrote the paper: FB MS.

References

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
2. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302–6309.
3. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781–791.
4. Cohen SJ, Punj CJ, Iannotti N, Saidman BH, Sabbath KD, et al. (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223–1229.
5. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29: 1556–1563.
6. Pumoune EA, Arwal S, Liu W, Raja R, Fine BM, et al. (2012) Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18: 2391–2401.
7. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, et al. (2012) Analysis of Circulating Tumor Cells in Patients with Non-Small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. J Thorac Oncol 7: 306–315.
8. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, et al. (2012) Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Micrometastasis in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology 30: 525–532. doi:10.1200/JCO.2010.33.3716.
9. Danila DC, Heller G, Gignac GA, Gonzalez-Espinosa R, Anand A, et al. (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053–7068.
10. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442–454.
11. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277: 301–308. doi:10.1111/j.1742-4658.2009.07448.x.
12. Sequist LV, Yang JCH, Yamamoto N, O’Byrne K, Hirsh V, et al. (2013) Phase III Study of Afatinib or Capecitabine Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology 31: 3327–3334. doi:10.1200/JCO.2012.44.2906.
13. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Otsuji S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380–2389.
14. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239–246.
15. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 803–809.
16. Kimura H, Suminor M, Kasahara K, Sone T, Araya T, et al. (2007) Evaluation of epidermal growth factor receptor status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97: 778–784.
17. Bai H, Mao L, Wang HS, Zhao J, Yang L, et al. (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239–246.
18. Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, et al. (2009) Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 15: 2630–2636.
19. Butitta F, Feliciou L, Del GM, Filice G, Di LA, et al. (2013) Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing. Clin Cancer Res 19: 691–698.
20. Cristofanilli M, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213–3221.
21. Sanger N, Effenberger KE, Riethdorf S, Van H V, Gauwerky J, et al. (2011) Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer 129: 2522–2526.
22. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818–829.
23. Yu M, Bardia A, Witmer BS, Stott SL, Smaus ME, et al. (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339: 589–594.
24. Pailler E, Adam J, Barbélémy A, Oulhen M, Auger N, et al. (2013) Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 31: 2273–2281. doi:10.1200/JCO.2012.44.5932.
25. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, et al. (2012) Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA 109: 14508–14513. doi:10.1073/pnas.1205422108.
26. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, et al. (2012) Detection of ultrarare mutations by next-generation sequencing. Proc Natl Acad Sci USA 109: 14508–14513. doi:10.1073/pnas.1205422108.